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Background: A phase I/II study was first conducted for the treat-
ment of stage I non-small cell lung cancer (NSCLC) from 1994 to
1999 to determine the optimal dose. On the basis on the results, a
phase II study using a regimen of four fractions during 1 week was
performed. The purpose of the present study was to determine the
local control and 5-year survival rates.
Methods: From December 2000 to November 2003, 79 patients with
80 primary lesions were treated. Using a fixed dose of 52.8 GyE for
stage IA NSCLC and 60.0 GyE for stage IB NSCLC in four fractions
during 1 week, the primary tumors were irradiated with carbon beams
alone. The average age of the patients was 74.8 years. Sixty-two
(78.5%) of these patients were medically inoperable. Local control and
survival were determined using the Kaplan–Meier method. The data
were statistically processed using the log–rank test.
Results: All patients were observed for a minimum of 3 years or
until death, with a median follow-up time of 38.6 months, ranging
from 2.5 to 72.2 months. The local control rate for all patients was
90% (T1: 98%, T2: 80%). The patients’ 5-year lung cancer–specific
survival rate was 68% (IA: 87%, IB: 42%). The overall survival was
45% (IA: 62%, IB: 25%). Half of the deaths were attributable to
intercurrent diseases. No toxic reactions in the lung greater than
grade 3 were detected.
Conclusion: Carbon ion beam radiotherapy with a regimen of four
fractions during 1 week has been proven as a valid alternative to
surgery for stage I NSCLC and to offer particular benefits, especially
for elderly and inoperable patients.
Key Words: Heavy particles, Carbon ion beams, Four fractions,
Non-small cell lung cancer, Stage I.
(J Thorac Oncol. 2007;2: 916–926)
In 1998, lung cancer became the leading cause of cancer-related deaths in Japan, as it is in Western countries.
Surgery plays a pivotal role in the curative treatment for
non-small cell lung cancer (NSCLC), but it is not necessarily
the best treatment for elderly persons and/or patients with
cardiovascular and pulmonary comorbidities. Yet, as an al-
ternative, conventional radiotherapy produced a 5-year sur-
vival rate of merely 15% to 30%.1,2 These results were quite
inferior to those achieved with surgery.3,4 Recently, new
modalities5 such as stereotactic radiotherapy6,7 and proton
radiotherapy8,9 have been tried but have not yet been dem-
onstrated as valid alternatives.
Heavy particle beams penetrate the body and abruptly
stop to form a Bragg peak as energy is lost. A considerable
amount of energy is deposited, resulting in dense ionization,
affording a high–linear energy transfer (LET).10 These phys-
ical properties help achieve excellent dose localization for
deep-seated tumors, sparing critical normal organs while high
LET exerts a powerful biological effect. It can be expected
that heavy particle beams can improve tumor control without
increasing toxicity.
In 1984, the Japanese government decided to construct
the heavy ion medical accelerator in Chiba (HIMAC) at our
institute (NIRS). HIMAC was completed in November
1993.11 For clinical use, carbon ion beams were selected on
the basis of preclinical experiments.12 The phase I/II clinical
trials with carbon ion radiotherapy (CIRT) for stage I NSCLC
were initiated in October 1994 and concluded in February
1999. As a result of dose-escalation studies, regimens of 90
GyE (gray equivalents) in 18 fractions during 6 weeks (NIRS
protocol #9303) and 72 GyE in nine fractions during 3 weeks
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(#9701) were chosen as the optimal dosages.13 After the
phase I/II study, we have conducted two successive phase II
studies. The first study used a regimen of nine fractions
during 3 weeks (#9802) and has already been reported. It
resulted in a local control of 96% and 5-year lung cancer–
specific and overall survival rates of 75% and 50%.14
Below, we present the results of the second study (#0001),
which used a regimen of four fractions during 1 week.
METHODS
Carbon Ion Beams, HIMAC, and
Treatment Systems
Carbon ion beams with 290, 350, and 400 MeV of
nucleon energy were generated in the HIMAC synchrotron
and delivered through its transport system to the irradiation
system in the treatment room. In this system, the beams are
broadened and shaped to a three-dimensional tumor contour.
For three-dimensional dose delivery, the key technology is to
spread out a sharp, monoenergetic Bragg peak (SOBP) of
carbon ion beams by using a range modulator to cover the
tumor thickness.10,12 The reference point was set so it would
be the center of SOBP. In this procedure, the patients were
immobilized with custom-made devices in a semicylindri-
cally shaped rotary capsule set on a computed tomography
(CT) couch or a treatment couch. CT planning is performed
using the HIPLAN,15 which was specifically developed for
three-dimensional treatment planning with respiratory-gated
CT images. Patient positioning and verification are performed
using the patient set-up devices, digital reconstructed radio-
graphs, online portal fluoroscopic radiographs, and metal
markers made of iridium wire as a landmark. A respiratory-
gated irradiation system was developed and employed to
minimize respiratory movements of the tumor and to reduce
treatment volume.16
The carbon ion radiation dose was expressed in terms
of gray equivalents (GyE). GyE values are calculated by
multiplying the physical dose with the relative biological
effectiveness (RBE), which is approximately 3.0 at 0.8 cm
from the distal end of the SOBP.10,12
Study Design
Patients were stratified into two groups according to
tumor size, T1 (3.0 cm) and T2 (3.0 cm). Using a regimen
of four fractions during 1 week, T1 and T2 were treated with
carbon ion beams in total doses of 52.8 and 60 GyE. The
primary endpoints were acute toxicity and local control (3
years). The secondary endpoints were tumor response and
survival. The protocol (#1000) was designed by the Working
Group for Lung Cancer.
Patient Eligibility
Patients with a peripheral type of stage I NSCLC who
were inoperable or refused surgery were eligible for this study.
Primary tumor had to be histologically proven and measurable.
The patient’s performance status (PS) was between 0 and 2
according to the World Health Organization criteria. The patient
had to have no history of radiotherapy to the target, and no prior
chemotherapy within 4 weeks of therapy. They had to have no
intractable infection and active multiple cancers. Each patient
gave his or her written informed consent, which was approved
by the ethics committee at our institute. After therapy, the
patients’ progress was verified twice a year by the members of
the Working Group for Lung Cancer.
Staging, Follow-up, and Assessment of Results
For staging, CT scans of the chest and upper abdomen
and enhanced MRI scans of the brain, bone scans, and
bronchoscopy were routinely performed. A 11C-methionine
positron emission tomography scan was routinely taken for
confirmation.17 Regional lymph nodes greater than 1 cm in
the short axis on the contrast-enhanced CT images were taken
to serve as evidence of positive metastasis. Clinical staging
was performed according to the International Union Against
Cancer tumor, node, metastasis classification.3 During the
first year, follow-up studies were performed at 1, 2, 3, 6, and
12 months, with a short hospital admission for thorough
examination. In the next year, these checkups were performed
at intervals of 3 months or twice a year, and in the third year
and thereafter they were performed at intervals of 6 months
and then once or twice a year. Toxicity on organs such as the
skin and lung was assessed according to the Radiation Ther-
apy Oncology Group (acute) and Radiation Therapy Oncol-
ogy Group/European Organization for Research and Treat-
ment of Cancer (late) classifications.18 Tumor response was
determined at maximum regression within 6 months by CT
after the onset of therapy according to the World Health
Organization definition.19 Local control was defined in terms
of the absence of evidence of tumor.20 The irradiated primary
tumors were carefully followed with studies, including tumor
markers; routine, enhanced, high-resolution CT scans; and
bronchoscopy. Once a recurrence was suspected, a positron
emission tomography scan and then bronchoscopy were per-
formed for confirmation. Cause-specific morbidity was deter-
mined in terms of death caused by treatment-related cancer or
as a result of the active disease.20
Treatment
Primary tumors were the only targets irradiated with
carbon beams at a fixed dose of 52.8 GyE (13.2 GyE/fraction)
for stage IA NSCLC and 60.0 GyE (15 GyE/fraction) for
stage IB NSCLC in the regimen of four fractions during 1
week. Prophylactic elective node irradiation was not per-
formed. In targeting, a visible lesion on the CT image in the
soft-tissue condition was defined as the gross tumor volume.
The clinical target volume was determined by setting the
margin more than 10 mm outside the gross tumor volume. To
allow for the movement of the target during gated respiration,
the internal margin was set by 5 mm outside the clinical target
volume. The planning target volume (PTV) was defined as
clinical target volume  internal margin.21,22 The boluses
were designed 3 mm away from the PTV at the proximal and
distal ends of the SOBP, respectively. Multileaf and patient
collimators were designed at 6 and 3 mm, respectively, from
PTV, to which more than 90% of the prescribed dose was
delivered. Set-up corrections were carried out so that target
volumes would be less than 2 mm three-dimensionally at every
treatment, by using iridium markers installed in the lung.
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Four oblique portals at mutual angles of 40 or 50 degrees
were used to achieve a better dose distribution for all (80)
primary tumors. In practice, the planning CT was performed for
a patient who was immobilized and fixed in the rotating position.
For treatment, the patient was irradiated in the same position. A
respiratory-gated irradiation system was employed for all pa-
tients. The average target volume (i.e., PTV) was 90.0  55.6
ml: 54.45  26.07 ml (T1) and 123  49.91 ml (T2). The
volume with a dose greater than 20 GyE was 178.0  94.4 ml,
5.73  2.63%: 145.03  56.26 ml, 4.73  2.21% (T1) and
222.70  105.53 ml, 6.76  2.73% (T2). Figure 1 shows a
dose-distribution map for a representative case. These treatment-
related factors are summarized in Table 1a.
Statistical Analysis
The local control, lung cancer–specific survival, and
overall survival rates were obtained using the Kaplan–Meier
method. Significance among survival curves was tested using
log–rank, Breslow, and Tarone–Ware alone or in combina-
tion (p  0.05). Multivariate analysis was performed using
the Cox proportional hazards model to test the significance of
various factors with regard to survival. All statistical analyses
were performed using SPSS software (version 8).
A comparison of all pulmonary function indexes was
made using repeated measurements and analysis of variance,
using the Dunnett test for post hoc comparison only when the
results of the analysis of variance were significant at p  0.05.
RESULTS
Patient Characteristics
The protocol for the study opened in December 2000
and closed in November 2003. During the 3 years, 79 patients
FIGURE 1. (A) Axial image: dose
distribution for tumor (right lower
lobe) receiving a total carbon ion
dose of 60 GyE from four directions
(four portals). Yellow line, planning
target volume; red line, 96% of the
prescribed dose; orange line, 90%;
green line, 50%; blue line, 30%; vio-
let line, 10%. (B) Frontal image. (C)
Sagittal image.
TABLE 1A. Treatment Characteristics
0001 T1 T2
Number of treated lesions 79 42 37
Fractionation 4 fractions/1 week 4 fractions/1 week
Total dose GyE (fraction dose) 52.8 60
Number of four portals 80 42 38
Respiratory-gated irradiation 79 42 37
Target volume (ml)* 86.74  50.71 54.45  26.07 123.40  46.91
V20 GyE (ml)† 176.62  93.23 146.03  56.26 222.70  105.53
(%) 5.68  2.64 4.73  2.12 6.76  2.73
Energy of carbon beams: 290, 350, and 400 MeV/U.
*Planning target volume.
†Irradiated volume (ml, %) at a dose greater than 20 GyE.
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were registered. The 79 patients with 80 primaries were
subjected to this analysis. All protocol data were evaluated by
November 30, 2006. All of the 79 patients with 80 lesions
were individually analyzed. One of them had bilateral prima-
ries developed as synchronous tumors and independently
according to Martini and Melamed23: the first was located at
the left upper lung, and the second appeared at the right lower
lung after 1 year, and both were treated with CIRT, in this
order. His survival was measured after the first treatment.
As shown in Table 1b, their age ranged from 47 to 88
years, with a mean of 74.8 years; 54 (68%) were male and 25
(32%) were female. There were 53 adenocarcinomas, 24
squamous cell carcinomas, 2 large-cell carcinomas, and 1
adenosquamous carcinoma. There were 8 patients with PS 0,
68 patients with PS 1, and 3 patients with PS 2. There were
33 patients with high lactate dehydrogenase (LDH), and four
patients with weight loss 3 kg, The average tumor size was
29.9 mm, ranging from 10 to 70 mm, and the heaviness of
smoking was 39.4 pack-years. There were 17 patients
(21.5%) who had refused surgery and 62 patients (78.5%)
who were medically inoperable, with 50 of them presenting
with poor pulmonary function attributable to chronic ob-
structive pulmonary disease, idiopathic pulmonary fibro-
sis, old tuberculosis, thoracic deformity, and previous lung
TABLE 1B. Patient Characteristics and Reasons for Inoperability
Protocol Number 0001 T1 T2
Patient number 79 42 37
Lesion number 80* 42 38
Age (yr) 74.8 (47–88) 73.4 (47–86) 76.4 (60–88)
Gender†
Male 54 24 30
Female 25 18 7
PS
0 8 4 4
1 68 37 31
2 3 1 2
Weight loss (3 kg) 4 0 4
T factor: stage (5 cm) 5 0 5
Tumor size (mm)‡ 29.9 (10–70) 21.6 39.1
Histology
AD 53 31 22
SQ 24 11 13
L 2 0 2
Ad-Sq 1 0 1
LDH  normal value 47 27 20
Location
Upper 29 14 15
Middle 8 3 5
Lower 43 25 18
Smoking history (pack-years)§ 39.4 (0–127.5) 35.5 (0–128) 43.6 (0–107.5)
Refusal of surgery 17 (21.5%) 11 6
Medical inoperability 62 (78.5%) 31 31
Pulmonary 50 26 24
COPD 25 11 14
IPF 2 1 1
BA 4 3 1
TB 1 0 1
Thoracic deformity 6 3 3
Previous lung resection 12 8 4
Cardiovascular 8 3 5
Advanced aged 4 2 2
*Only one among the 79 patients had two T1 primary lesions in his left upper and right lower lobes, developed at a 1-year interval, for
which he received carbon ion radiotherapy heterochronously twice, so that 80 primary tumors were evaluated to tumors response and local control.
†p  0.0123 (2) test.
‡At the greatest axis.
§Smoking history was measured in number of packs per day, and years of smoking. The normal value was 101 to 200 U/ml.
For refusal of surgery, 21.5%; for medical inoperability, 78.5%.
PS, performance status; AD, adenocarcinoma; SQ, squamous cell carcinoma; L, large-cell carcinoma; Ad-Sq, adenosquamous carcinoma; LDH,
lactate dehydrogenase; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; BA, bronchial asthma; TB, tuberculosis.
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resection. The others were with cardiovascular disease and
advanced age.
The number of T1 and T2 was 42 for 42 patients with
stage IA and 38 for 37 patients with stage IB each. Gender
showed a significant difference (p  0.023) only in the
various items between T1 and T2.
Tumor Response, Local Control, and Survival
No patients were lost to follow-up. All patients were
observed for a minimum of 3 years or until death, with a
median follow-up time of 38.6 months, ranging from 2.5 to
72.2 months. Three patients were excluded for evaluation of
tumor response because of early death. A tumor response was
6.5% (5/77) in complete recovery consisting of 0% (0/40) for
T1 and 8.3% (5/37) for T2, 58.4% (45/77) in partial recovery
consisting of 57.5% (23/40) for T1 and 59.4% for T2 (22/37),
and 35% (27/77) in no change consisting of 42.5% (17/40)
for T1 and 27% (10/37) for T2.
As shown in Figure 2, the 5-year local control rate for
80 lesions by the Kaplan–Meier method was 90%, and the
5-year lung cancer–specific and overall survival rates for the
79 patients were 68% and 45%, respectively. In the substage,
as shown in Figure 3, the 5-year cause-specific survival rates
for patients with stage IA (42) and stage IB (37) were 87%
and 42%, and the 5-year overall survival rates with stage IA
and IB were 62% and 25%, respectively.
Local recurrence was clinically observed in 7 of the 80
(8.75%) primary lesions. Four of them were squamous cell
carcinomas, and three were nonsquamous carcinomas. Local
recurrence occurred from 7.1 to 21.5 months, with a medium
of 12.5 months. All but one recurred from T2 tumor (Table 2).
The Kaplan–Meier method (Figure 4a) showed that the
local control of T1 was 97%, whereas that of T2 was 80%.
The difference in tumor-control rate between T1 and T2 was
significant (p  0.0197). In histologic type (Figure 4b), the
tumor control of 24 squamous-type tumors was 83%, and that of
56 non–squamous-type tumors was 94%. Nevertheless, there
was no difference between the two histologic types (p 0.134).
On multivariate analysis (Table 3), significant (p 
0.05) factors for improved lung cancer–specific survival were
no local recurrence (p  0.015) and smaller tumor size (p 
0.003), and for overall survival, the only significant factor
was smaller tumor size (p  0.004). For local control, only a
high value of LDH was a significant factor (p  0.05).
Pattern at the First Recurrence Site and Cause
of Death
Forty-eight of the 79 patients (60.8%) had no recur-
rence, whereas 31 patients (39.2%) had recurrences. All
instances of recurrence occurred from 1 to 31 months (me-
FIGURE 2. Five-year local control, overall survival, and
cause-specific survival in 79 patients with 80 stage I non-
small cell lung cancer after the start of carbon beam
therapy.
FIGURE 3. (A) Local control, overall survival, and cause-
specific survival in 42 patients: patients with stage IA non-
small cell lung cancer (n  42). (B) Local control, overall sur-
vival, and cause-specific survival in 37 patients: patients with
stage IB non-small cell lung cancer.
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dian, 15 months) after the commencement of therapy. Table
4 gives the number of patients who had their first recurrence
by site for stages IA and IB. One primary recurrence and no
regional node metastases occurred in stage IA. The one
TABLE 2. Patients With Primary Recurrence
Age Gender T Factor Size (mm) Histology Site Dose (GyE)
Recurrence
Time (months)
Y.K. 78 Female T2 40  32 SQ Right S10 60 7.1
S.K. 67 Male T1 28  25 AD Left S6 52.8 7.6
S.A. 81 Male T2 42  42 SQ Right S10 60 12.5
S.O. 76 Male T2 31  28 SQ Right S7 60 12.6
T.N. 75 Female T2 40  33 Ad-Sq Right S2 60 13
K.S. 77 Male T2 45  35 SQ Left S5 60 14.5
M.K. 60 Male T2 46  30 AD Right S4 60 21.5
Recurrence time  time after therapy. SQ, squamous cell carcinoma; AD, adenocarcinoma; Ad-Sq, adenosquamous carcinoma.
FIGURE 4. (A) Local control rate by T1 and T2 (p  0.019).
(B) Local control by squamous and nonsquamous cell carci-
noma (p  0.134). p values were calculated by the log–rank
test.
TABLE 3. Multivariate Analysis of Factors Influencing
Overall, Cause-specific Survival, and Local Control
Factors Overall (80)
Cause
Specific (80)
Local
Control (81)
p value*
Age† 0.396 0.058 0.282
Gender 0.674 0.457 0.109
PS‡ 0.124 0.975 0.052
Weight loss§ 0.162 0.319 0.793
Pack-years† 0.772 0.576 0.578
Inoperability 0.756 0.434 0.619
LDH  normal value 0.906 0.966 0.050
Tumor size† 0.003 0.003 0.224
Histology 0.131 0.068 0.072
Multiple cancer 0.424 0.088 0.354
Local control¶ 0.240 0.015 —
*p values: Cox hazard model. p  0.05 log–rank.
†Continuous variables.
‡PS: 0 vs. 12.
§Weight loss: 3 kg loss vs. 3 kg.
Inoperability: medical inoperability vs. refusal of surgery.
¶Local control: recurrence vs. no recurrence.
TABLE 4. First Recurrence Site After Carbon Ion
Radiotherapy (0001)
IA IB
Total 79 42 37
Recurrence 31 (39.2%) 8 (19.0%) 23 (62.2%)
Primary only 7 1 6
Regional node only 3 0 3
PM 1 1 0 1
Pleuritis carcinomatosa 5 2 3
Distant metastasis 15 5 10
No recurrence 48 (60.8%) 34 (81.0%) 14 (37.8%)
PM 1, intralobar pulmonary metastasis.
Lung: 6; bone: 1; liver: 1; brain: 5; multiple: 2.
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patient with primary recurrence was treated with Liniac
irradiation at a dose of 60 Gy and then chemotherapy; this
patient has survived with the tumor for 35 months after CIRT.
Six primary recurrences and four regional metastases consist-
ing of three regional nodes and one intralobar metastasis
occurred in stage IB after the first CIRT. Five of the six
primary recurrences were retreated with Liniac irradiation at
a dose of 60 Gy, but all of them did recur, and four of them
are already dead, whereas two live with cancer. The remain-
ing patient received surgery and still survives. Four cases
with regional metastasis were retreated with CIRT and sur-
vive without cancer. There were five patients with pleuritis
carcinomatosa, consisting of two for stage IA and three for
stage IB, and 15 patients with six distant metastases, one
bone, one liver, five brain, and two more metastases to other
sites. All of the pleuritis carcinomatosa cases died from
disease progression. Eleven of 15 patients with metastases
died of disease progression. The total incidence of first
recurrence for stage IB (62%) was higher than for stage IA
(19%). Verification by the 2 test showed a significant dif-
ference (2  16.8).
As indicated in Table 5, 37 of 79 patients (46.8%),
consisting of 5 with cancer and 28 without cancer, are alive.
On the other hand, 42 patients (53.2%) are dead, consisting of
21 primary-related lung cancer deaths (26.5%) attributable to
four primary recurrences, six pleuritis carcinomatosa, and 11
distant metastases (six lung, one liver, one bone, one brain,
and two multiple organs), and 21 intercurrent deaths (26.5%)
attributable to 15 noncancerous diseases (two cerebral bleed-
ing, three heart failure, one myocardial infarction, seven
pneumonia, and two respiratory failure), and 6 other cancers
(two liver cancer, one prostate cancer, one colon cancer, one
acute myeloid leukemia, and one malignant lymphoma). Only
5 patients out of 42 (12%) with stage IA and 16 patients out
of 37 (43.2%) with stage IB died of primary-related disease.
On the other hand, 11 patients of 42 (26%) with stage IA and
10 patients of 37 (27%) with stage IB died of intercurrent
disease. There was no significant difference in causes of
death between T1 and T2 (2  0.98).
Toxicity
The adverse effects after CIRT are shown in Table 6.
The skin reactions were evaluated for 80 regions of the 79
patients for early reactions and 77 regions for late reactions,
because three patients were lost to observation. There were
75 regions at grade 1 and 5 regions at grade 2 for early skin
reactions, and 76 regions at grade 1 and 1 region at grade 2
for late skin reaction. Grade 2 for early skin reaction was
observed in two patients with stage IA and in three patients
with stage IB. The lung reactions were clinically assessed for
79 patients for early reactions and for 76 patients for late
reactions, because three patients were lost to observation.
There were 78 patients at grade 0 and 1 patient at grade 2 for
early reactions. There were 7 patients at grade 0, 68 patients
at grade 1, and 1 patient at grade 2 for late reactions. No grade
3 reactions were observed for either reaction. Grade 2 for
early and late lung reactions were observed in one patient
with stage IA and in one patient with stage IB, respectively.
Pulmonary function tests were performed before and at 6
and 12 months after irradiation for 48 patients (Table 7). As a
result, forced expiratory in 1 second was reduced by 8% (p 
0.01), forced vital capacity by 7% (p  0.05), vital capacity by
6% (p  0.05), and total lung capacity by 7% (p  0.01) at 12
months after irradiation. Nevertheless, diffusing capacity for
carbon monoxide and diffusing capacity for carbon monoxide/
alveolar volume were not significantly reduced. The magnitude
of the decrease in all pulmonary function indexes was10% at
12 months after CIRT.
Nine of the 79 patients (11.4%) complained of costal
bone pain, and tenderness around the part of the skin receiv-
ing carbon beams appeared at a median time of 10 months
TABLE 5. Cause of Death
0001 Stage IA Stage IB
(n  79) (n  42) (n  37)
Lung cancer death 21 5 16
Primary regrowth 4 0 4
Metastasis 15 5 10
Pleural dissemination 6 3 3
Distant metastasis 11 2 9
Intercurrent death 21 11 10
Noncancerous 15 7 8
Other cancer 6 4 2
Total 42 16 26
TABLE 6. Adverse Effects by Carbon Ion Radiotherapy (0001)
Early and Late Reactions Case (IA/IB)
Grade
0 1 2 3 4
Early (RTOG)
Skin 80 (42/38) 0 75 (40/35) 5 (2/3) 0 0
Lung 79 (41/38) 78 (41/37) 0 1 (0/1) 0 0
Late (RTOG/EORTC)
Skin 77 (40/37) 0 76 (40/36) 1 (0/1) 0 0
Lung 76 (40/36) 6 (4/2) 69 (35/34) 1 (1/0) 0 0
The reaction was evaluated according to Radiation Therapy Oncology Group (acute) and Radiation Therapy Oncology Group/European
Organization for Research and Treatment of Cancer (late) criteria.
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(range, 6–14 months) after the start of therapy. Slight swell-
ing of the bone and the surrounding soft tissue was observed
on visual inspection or CT scanning and disappeared within,
at most, 1 month thereafter. Three of them needed NSAIDs,
one needed morphine, and four needed no medication. Costal
bone fracture was observed in two of nine patients at 13 and
17 months after therapy, respectively.
DISCUSSION
A phase I/II study for the treatment of stage I NSCLC
by CIRT was first conducted using the dose-escalation
method to determine the optimal dose. The additional pur-
pose was to develop correct, reliable, and safe irradiation
techniques for CIRT. As reported in our phase I/II study,13
the following conclusions can be drawn: (1) the local control
rate was dose dependent22,24 and reached more than 90% at
90 GyE with a regimen of 18 fractions during 6 weeks and 72
GyE with a regimen of nine fractions during 3 weeks (grade
3 radiation pneumonitis occurred in 2.7% of patients); (2)
respiratory-gated and four-portal oblique irradiation, exclud-
ing opposed ports, proved successful in reducing the inci-
dence of radiation pneumonitis; (3) setting the provisional
target by allowing for the difference with CT value can
prevent marginal recurrence22; and (4) early detection of
nodal metastasis and then elective nodal irradiation with
carbon beams can prevent the survival rate from decreasing
further.
The local control rate was determined as a primary
endpoint in the present study because this directly influences
the survival of stage I NSCLC patients. In the previous phase
I/II study, it has been shown that local control by CIRT was
affected by dose and tumor size.13 According to tumor size,
we chose a different total dose at 52.8 GyE for stage IA
NSCLC (T1) and at 60 GyE for stage IB NSCLC (T2) using
a regimen of four fractions during 1 week, respectively. The
observation period required to determine the local control of
the irradiated lesions is at least 3 years.13 All patients of this
study were observed for a minimum of 3 years or until death,
with a median follow-up time of 38.6 months (range, 2.5–
72.2 months). For the correct assessment of local control of
the patients who could not be observed for such a long time
as they died of metastasis/dissemination or intercurrent dis-
ease, a histological approach by repeating bronchoscopy
proved useful.25 It was reported in the previous phase II study
(#9802)14 that we successfully collected the samples from the
irradiated primary lesions for 80% of all patients and found
that in all but one case, it was not possible to find viable
cancer cells suggestive of regrowth. Data not shown in the
present study show that similar results were obtained by
repeating bronchoscopy. Pathological responses for a whole
tumor were also observed in the specimens of T3 tumors
operated from the patients about 1 month after CIRT.26
These results are thought to be pathological evidence of a
high local control rate for the group of patients on short-
term observation.
As shown in Table 2, the local recurrence out of 80
primary cancers occurred in seven cases (8.6%). All events
occurred within 24 months, with a median time of 12 months
after CIRT. As shown in Figures 3 and 4, the local control
rate was significantly affected by tumor size (p 0.0197) but
not by histology (p  0.134). Multivariate analysis (Table 3)
indicates that the significant relationship with high LDH (p
0.05) may reflect some state of malignancy such as growth
rate and hypoxia.27 Compared with the phase II trial using
nine fractions during 3 weeks (#9802)14, the local control rate
became lower in this trial. It remains to be resolved in the
future whether the decrease of tumor control may be attrib-
utable to the total dose, the fraction number, or patient
characteristics between the two protocols.
The local control was reported to be 80% to 97% with
stage I treated by stereotactic radiotherapy.6,28,29 It was as-
sessed by CT but not confirmed until regrowth was clearly
identifiable, seeing that the CT images were often compli-
cated by induced fibrosis and/or atelectasia surrounding a
TABLE 7. Changes in Lung Function in 48 Patients at Follow-up (Men: 36; Women: 12; Age  75.73  4.93)
Before
Radiotherapy
Mean (SD)
Change at 6 Months After
Radiotherapy
Change at 12 Months After
Radiotherapy
Mean (SD) p % Mean (SD) p %
FEV1 (liters)
Observed 1.37 (0.56) 1.30 (0.55) NS 4 1.26 (0.55) 0.01 8
% predicted 60.58 (24.14) 58.23 (24.13) NS 4 56.42 (23.86) 0.01 7
FEV1/FVC (%) 58.46 (13.77) 58.85 (14.24) NS 1 59.00 (15.39) NS 1
FVC observed (liters) 2.33 (0.68) 2.22 (0.70) NS 4 2.16 (0.73) 0.05 7
VC (liters)
Observed 2.49 (0.72) 2.40 (0.71) NS 4 2.34 (0.73) 0.05 6
% predicted 88.18 (22.08) 85.06 (21.54) NS 4 83.40 (22.21) 0.01 5
TLC observed (liters) 4.84 (1.34) 4.70 (1.18) NS 3 4.49 (1.21) 0.01 7
RV/TLC (%) 47.90 (10.28) 47.77 (10.80) NS 0 47.61 (8.96) NS 1
Dlco (mL · min1 · mm Hg1) 10.32 (3.63) 10.59 (3.36) NS 3 9.68 (3.85) NS 6
NS, not significant; FEV1, forced expiratory in 1 second; FVC, forced vital capacity; VC, vital capacity; TLC, total lung capacity; RV, residual volume; DLCO, diffusing capacity
for carbon monoxide.
p values are the result of comparison with values before radiotherapy, using repeated-measures analysis of variance with Dunnett test.
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tumor. The follow-up period for these patients was 22 months
on average, ranging from 10 to 36 months. This period is
considered too short to define the true rate of local control.30
It might, therefore, be worthwhile to consider the perfor-
mance of tumor biopsy to search for residual tumor cells, as
has been done in our study.13,14,31
The lung cancer–specific survival rate of the present
cases was examined by the different stages. The rate (87%) of
stage IA in this trial was equal to that (89%) in the previous
9802 trial, whereas that of stage IB (42%) in this trial was
inferior to that of stage 1B (55%) in the 9802 trial by 13%.
The worse survival results in stage IB decreased the survival
rates of whole stage I to 68% in the 0001 trial compared with
75.7% in the 9802 trial. These rates are thought to be
attributable to the high rate (62.2%) of local recurrence and
distant metastasis (Table 4) for stage IB patients, with a
resulting higher death rate (Table 5). In multivariate analysis,
the lung cancer–specific survival was shown to be signifi-
cantly attributable to the failure of local control (p  0.016)
and tumor size (p  0.003; Table 3), but it was not shown to
be attributable to gender difference, as indicated in Table 1a.
Primary tumor was only the first target of CIRT. As
shown in Table 4, there were 11 locoregional recurrences
(14%): three regional nodes and one interlobar pulmonary
metastasis (PM1), in addition to seven primary recurrences.
Their incidence was slightly inferior to that of surgery.32
When the three regional but primary recurrences were diag-
nosed, CIRT was given to the two regional recurrences that
were controlled by retreatment irradiation for 6 and 29
months until death from heart failure and pneumonia, respec-
tively. The third case died of disease progression without
irradiation. One patient with PM near a primary tumor was
retreated with carbon ion beams at a dose of 48 GyE; this
patient then had regional node recurrence. The third treatment
of the node with carbon beams was performed at a dose of 48
GyE. This female patient is alive and has remained without
any tumor for longer than 4 years. Martini et al.33 report that
any resections less than lobectomy and no lymph node
dissection had adverse effects on recurrence and survival.
Our treatment strategy for regional recurrence, nevertheless,
is thought to have been validated as the standard surgical
procedure for stage I NSCLC.13,14
With clinical stage I NSCLC, our 5-year overall sur-
vival results (45%) were inferior to the surgical ones.3,4 The
survival difference may be attributable to age differences
between the two groups. The incidence of death attributable
to recurrence in the surgical group was 29%, whereas that of
death attributable to intercurrent diseases was 19%.32 On the
other hand, there was the same ratio of intercurrent death and
recurrence death (29%) among our patients (Table 5). Gen-
erally speaking, such increasing frequency of intercurrent death
might be attributable to the advanced age of our patients, who
were 10 years older on average than the surgical patients.
Compared with pulmonary damage reported in stereo-
tactic radiotherapy for stage I NSCLC,6,7 the incidence and
severity in our patients clearly seem low. Such a lower degree
of late lung damage was quantitatively confirmed by lung
function test Table 7. As shown in Table 1a, V20, which is a
useful parameter for predicting radiation pneumonia with
conventional radiotherapy,34 was 5.68  2.64% with CIRT.
Nagata et al.6 report that the V20 of patients with stage I
NSCLC treated by stereotactic radiotherapy was 1.0% to
11.6% (average  4.5%). There seems to be no substantial
difference in V20 between modalities. And, the magnitude of
decrease in all pulmonary function indexes was less than 10%
at 12 months after CIRT, almost the same as previously
reported,35 demonstrating that the patients in this trial suf-
fered less late lung damage. These less adverse effects for the
lung were achieved as a result of the excellent dose distribu-
tion achieved with carbon ion beams, with the formation of a
Bragg peak being different from an x-ray as a permeating
beam. Evidence may come to light in some future account for
the difference (low or high) in LET between these two
modalities.
In conclusion, the patients treated in this protocol were
about 10 years older than the patients treated by surgery, and
78.5% of the trial population (Table 1b) were judged to be
inoperable because of various complications. Nevertheless,
we attained a 90% local control rate, a 68.0% lung cancer–
specific survival rate, and a 45% overall survival rate. These
results measure up to those achieved with surgery. And,
CIRT seems to have the advantages of firm local control, less
lung damage, and a short term of irradiation with small fraction-
ation, although it does have the disadvantage of high cost
compared with stereotactic radiotherapy and proton therapy.
It has been more than a decade since we started carbon
beam therapy for lung cancer, using the HIMAC, in Novem-
ber 1994. Recently, two phase II studies (#9802 and #0001)
have demonstrated that CIRT for clinical stage I NSCLC
achieved a local control rate of more than 90% to 95%, a
5-year overall survival rate of 45% to 60%, and a lung
cancer–specific survival rate of 65% to 80%. These results
were equal to those by surgery. Throughout the 10 years, the
treatment period and fractionation were shortened and less-
ened from 18 fractions during 6 weeks to nine fractions
during 3 weeks and, further, to four fractions during 1 week.
Finally, it reached a single dose.36 To date, 140 patients have
been treated with single doses, with doses increasing 28, 32,
34, 36, 38, 40, 42, and 44 GyE since April 2003, and
single-dose CIRT therapy has been shown to lead to low
morbidity and high quality of life. Though we have not finally
determined which fractionation is best for the treatment of
peripheral-type stage I NSCLC, CIRT, which is an excellent
new modality in terms of a high quality of life and activities
of daily living, is a valid alternative to surgery for stage I
cancer, especially for elderly and inoperable patients.
Contributors
Members of the Working Group for Lung Cancer.
H. Owada, Department pf Basic Pathology, Graduate
School Of Medicine Chiba University, Chiba.
H. Kato, Department of Surgery, Tokyo Medical Col-
lege, Tokyo.
H. Kimura, Division of Thoracic Disease, Chiba Can-
cer Center, Chiba.
Miyamoto et al. Journal of Thoracic Oncology • Volume 2, Number 10, October 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer924
T. Kuriyama, Department of Respiratology, Graduate
School of Medicine, Chiba University, Chiba.
T. Koike, Departments of Thoracic Surgery and Pul-
monary Medicine, Niigata Cancer Center Hospital, Niigata.
T. Kodama, Division of Medical Oncology, National
Cancer Center Hospital, Tokyo.
K. Kobayashi, Department of Surgery, Keiyo Univer-
sity, Tokyo.
T. Kondo, Department of Respiratory Surgery, Tohoku
University, Sendai.
T. Goya, Department of Surgery, Kyorin University,
Tokyo.
K. Takagi, Department of Thoracic Cardiovascular Sur-
gery, Toho Department of Respiratory Surgery, Tokyo.
R. Tuchiya, Division of Thoracic Surgery, National
Cancer Center Hospital, Tokyo.
T. Nakano, Department of Radiology, Gunma Univer-
sity, Maebashi.
Y. Nishiwaki, Division of Diagnostic Oncology, Na-
tional Cancer Center, Hospital East, Chiba.
M. Higashiyama, Department of Thoracic Surgery,
Osaka Medical Center for Cancer and Cardiovascular Dis-
eases, Osaka.
T. Yamashita, Division of Radiology, Cancer Institute
Hospital, Tokyo.
ACKNOWLEDGMENTS
We are indebted to Suho Sakata, PhD, for his advice
and to Gen Kobashi at NIRS for statistical analysis. Thanks
are also due to Mr. Keisuke Yamakawa, Hitachi Electric
Company, for his help in statistical analysis and data man-
agement, and to Ms Kazuko Nakajima for her secretarial
support. We are indebted to Masao Oto, MD, and Hidemi
Owada, MD, for useful discussion, and Kamada Tadashi,
MD, Hiroshi Tujii, MD, Hirotoshi Kato, MD, Shingo Kato,
MD, Shieru Yamada, MD, Reiko Imai, MD, and Riwa Kishi-
moto, MD, for their constant support. This study was sup-
ported by the National Institute of Radiological Sciences
(NIRS) under its research project on heavy ions at NIRS-
HIMAC.
REFERENCES
1. Sibley GS. Radiotherapy for patients with medically inoperable stage I
non-small-cell lung cancer. Cancer 1998;82:433–438.
2. Jeremic B, Classen J, Bamberg M. Radiotherapy alone technically
operable, medically inoperable, early-stage (I/II) non-small-cell lung
cancer. Int J Radiat Oncol Biol Phys 2002;54:119–130.
3. Mountain CF. Revisions in the international system for staging lung
cancer. Chest 1997;111:1710–1717.
4. Naruke T, Tsuchiya R, Kondo H, et al. Prognosis and survival after
resection for bronchogenic carcinoma based on the 1997 TNM-staging
classification: the Japanese experience. Ann Thorac Surg 2001;71:1759–
1764.
5. Schild SE, Bogart JA. Innovation in the radiotherapy of non-small cell
lung cancer. J Thorac Oncol 2006;1:85–92.
6. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase
I/II study of 48Gy of stereotactic body radiotherapy in 4 fractions for
primary lung cancer using a stereotactic body frame. Int J Radiat Oncol
Biol Phys 2005;63:1427–1431.
7. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated
high-dose irradiation for stage I nonsmall cell lung carcinoma. Cancer
2004;101:1623–1631.
8. Bush DA, Slater JD, Bonnet R, et al. Proton-beam radiotherapy for early
stage lung cancer. Chest 1999;116:1313–1319.
9. Shioyama Y, Tokuuye K, Okumuma T, et al. Clinical evaluation of
proton radiotherrapy for non-small-cell lung cancer. Int J Radiat Oncol
Biol Phys 2003;56:7–13.
10. Kanai T, Furusawa Y, Fukutsu K, et al. Irradiation of mixed beam and
design of spread out Bragg peak for heavy-ion radiotherapy. Radiat Res
1997;147:78–85.
11. Hirao Y, Ogawa H, Yamada S, et al. Heavy ion synchrotron for medical
use—HIMAC project at NIRS-JAPAN. Nucl Phys A 1992;538:541c–550c.
12. Kanai T, Endo M, Minohara S, et al. Biophysical characteristics of
HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J
Radiat Oncol Biol Phys 1999;44:201–210.
13. Miyamoto T, Yamamoto N, Nishimura Y, et al. Carbon ion radiotherapy for
stage I non-small cell lung cancer. Radiother Oncol 2003;66:127–140.
14. Miyamoto T, Baba M, Yamamoto N, et al. Curative treatment of stage
I non-small cell lung cancer with carbon ion beams using a hypofrac-
tionated regimen. Int J Radiat Oncol Biol Phys 2007;67:750–758.
15. Endo M, Koyama-Ito H, Minohara S, et al. Hiplan—a heavy ion
treatment planning system at HIMAC. J Jpn Soc Ther Radiol Oncol
1996;8:231–238.
16. Minohara S, Kanai T, Endo M, et al. Respiratory gated irradiation
system for heavy-ion radiotherapy. Int J Radiat Oncol Biol Phys 2000;
47:1097–1103.
17. Yasukawa T, Yamaguchi Y, Aoyagi H, et al. Diagnosis of hilar and
mediastinal lymph node metastasis of lung cancer by positoron emission
tomography using 11C- methionine. Jpn J Lung Cancer 1996;36:919–926.
18. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy
oncology group (RTOG) and the European organization for research and
treatment of cancer (EOR TC). Int J Radiat Oncol Biol Phys 1995;31:
1341–1346.
19. Definition of Objective Response. In WHO Handbook for Reporting the
Results of Cancer Treatment. Geneva, Switzerland: World Health Or-
ganization, 1979. Pp. 23–25. Offset publication no. 48.
20. Bentzen SM. Towards evidence based radiation oncology. improving the
design, analysis, and reporting of clinical outcome studies in radiother-
apy. Radiother Oncol 1998;46:5–18.
21. Ekberg L, Holmberg O, Wittgren L, et al. Application of ICRU report
50. How should margins be added to the clinical target volume when
defining the planning target volume, as exemplified for lung cancer.
ICRU News December 1997:4–9.
22. Koto M, Miyamoto T, Yamamoto N, et al. Local control and recurrence
of stage I non-small cell lung cancer after carbon ion radiotherapy.
Radiother Oncol 2004;71:147–156.
23. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac
Cardiovasc Surg 1975;70:283–293.
24. Kanai T, Matsufuji N, Miyamoto T, et al. Examination of GyE system for
HIMAC carbon therapy. Int J Radiat Oncol Biol Phys 2006;64:650–656.
25. Arriagada R, Chevalier TL, Quoix E, et al. ASTRO plenary: effect of
chemotherapy on locally advanced non-small cell lung carcinoma: a
randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991;
20:1183–1190.
26. Yamamoto N, Miyamoto T, Nishimura H, et al. Preoperative carbon
ion radiotherapy for non-small cell lung cancer with chest wall
invasion-pathological findings concerning tumor response and radi-
ation induced lung injury in the resected organs. Lung Cancer
2003;42:87–95.
27. Blancher C, Moor JW, Talks KL, et al. Relationship pf hypoxia-
inducible factor (HIF)-1 alpha and HIF alpha expression to vascular
endothelial growth factor induction and hypoxia survival in human
breast cancer cell lines. Cancer Res 2000;60:7106–7113.
28. Timmermen R, Papiez L, McCarry R, et al. Extracranial stereotactic
radioablation: results of a phase I study in medically inoperable stage I
non-small cell lung cancer. Chest 2003;124:1946–1955.
29. Wulf JW, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy for
primary cancer and pulmonary metastasis: a noninvasive treatment
approach in medically inoperable patients. Int J Radiat Oncol Biol Phys
2004;60:186–196.
30. Bogart JA. Definitive radiotherapy for stage I non-small cell lung
cancer. Ain’t nothing like the real thing? J Thorac Oncol 2006;8:
763–765.
Journal of Thoracic Oncology • Volume 2, Number 10, October 2007 Carbon Ion Radiotherapy for Stage I NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer 925
31. Asamura H. Treatment of choice for stage I non-small cell lung
cancer: surgery or radiotherapy? J Thorac Oncol 2006;8:766–767.
32. Harpole DH, Herndon JE, Yung WG, et al. Stage I nonsmall cell lung
cancer. A multivariate analysis of treatment methods and patterns of
recurrence. Cancer 1995;76:787–796.
33. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and
second primary tumors in resected stage I lung cancer. J Thorac
Cardiovasc Surg 1995;109:120–129.
34. Graham MV, Purdy JA, Emaimi B, et al. Clinical dose-volume histo-
gram analysis for pneumonitis after 3D treatment for non-small cell lung
cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323–329.
35. Kadono K, Homma T, Naitoh A, et al. The effect of heavy ion particle
irradiation on lung function in patients with stage I non-small cell lung
cancers. Chest 2002;122:1925–1932.
36. Miyamoto T. Carbon beam radiotherapy. Jpn J Lung Cancer 2004;44:
741–751.
Miyamoto et al. Journal of Thoracic Oncology • Volume 2, Number 10, October 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer926
